Filing Flows

Filing Flows › 8-K events › Inogen

Inogen: completion of an acquisition or disposition of assets

Form 8-K filed Nov 5, 2026 · items 2.01, 2.02, 5.02, 7.01, 8.01

Mergers and acquisitionsInogen Announces Leadership Transition

What the filing says

On November 2, 2026, Inogen, Inc. (“Inogen” or the “Company”) completed the previously announced sale of the United States oxygen rental business (the “Rental Business”) to Rotech Healthcare Inc. (“Rotech”), pursuant to the terms of the Asset Purchase Agreement, dated as of September 29, 2026 (the “Asset Purchase Agree

Read the filing on SEC EDGAR →

What usually followsAcross 2,671 8-Ks reporting Item 2.01 (completed acquisition or disposition) in our universe, the stock's median move the next session was +0.1% (typical size ±1.6%, up 52% of the time); over the following 21 sessions, +1.2%. Item 2.02: +0.2% next session across 69,115. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Inogen at a glance

Latest quarterQ2 2026
Revenue$95.1M
Revenue Y/Y+3%
Operating margin-5.4%
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies

Inogen, Q2 2026: revenue $95.1M (+3% year over year), operating margin -5.4%. The chart follows the revenue to costs, profit and cash.

Inogen: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.